Fludarabine
Primary Cutaneous Anaplastic Large Cell Lymphoma
UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Primary Cutaneous Anaplastic Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin John Reneau | Phase 3 | BB |
Bexarotene Millennium Pharmaceuticals, Inc. | Phase 3 | BB |
Methotrexate Millennium Pharmaceuticals, Inc. | Phase 3 | BB |
Lenalidomide John Reneau | Phase 2 | B |
Pralatrexate Acrotech Biopharma Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative · Phase 2
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →